These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19349791)

  • 41. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
    Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
    Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
    Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
    López-Gálvez MI; García-Campos JM
    Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():38-45. PubMed ID: 24278988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
    Saito W; Kase S; Ohgami K; Mori S; Ohno S
    Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Avastin a treatment of diabetic macular edema].
    Stan C; Sevan S; Mureşan I
    Oftalmologia; 2011; 55(1):63-7. PubMed ID: 21774389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OCT and cataract.
    Falavarjani KG; Modarres M; Nikeghbali A
    Ophthalmology; 2010 Apr; 117(4):849; author reply 849-50. PubMed ID: 20346827
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2014 May; 231(5):527-34. PubMed ID: 24799173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab local complications.
    Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract]   [Full Text] [Related]  

  • 52. Intravitreal bevacizumab for branch retinal vein occlusion.
    Spandau U; Wickenhäuser A; Rensch F; Jonas J
    Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
    [No Abstract]   [Full Text] [Related]  

  • 53. Intravitreal foreign body following intravitreal anti-VEGF injection: a case report.
    Al Bdour MD; Ali ZR
    Eye (Lond); 2014 Feb; 28(2):244-5. PubMed ID: 24357842
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
    Salam A; Mathew R; Sivaprasad S
    Acta Ophthalmol; 2011 Aug; 89(5):405-11. PubMed ID: 21294854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term response of macular oedema to intravitreal bevacizumab.
    Welch DE; Elmariah H; Peden MC; Adams SG; Ratnakaram R; Kaushal S
    Br J Ophthalmol; 2009 Aug; 93(8):1033-6. PubMed ID: 19403519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M; Nagpal K; Nagpal PN
    Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ranibizumab for diabetic retinopathy.
    Rodriguez-Fontal M; Alfaro V; Kerrison JB; Jablon EP
    Curr Diabetes Rev; 2009 Feb; 5(1):47-51. PubMed ID: 19199898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anti-VEGF: one drug for different conditions?].
    Cohen SY; Massin P; Souied E
    J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
    [No Abstract]   [Full Text] [Related]  

  • 60. Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
    Călugăru D; Călugăru M
    Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):160. PubMed ID: 29554381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.